Država: Kanada
Jezik: engleski
Izvor: Health Canada
CARBAMAZEPINE
NOVARTIS PHARMACEUTICALS CANADA INC
N03AF01
CARBAMAZEPINE
200MG
TABLET
CARBAMAZEPINE 200MG
ORAL
100/500
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0108674001; AHFS:
APPROVED
1997-06-05
_PR_ _TEGRETOL_ _®_ _ carbamazepine tablets, _ _PR_ _TEGRETOL_ _® _ _CR carbamazepine controlled-release tablets, _ _PR_ _TEGRETOL_ _®_ _ SUSPENSION carbamazepine suspension _ _Page 1 of 49 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEGRETOL ® carbamazepine tablets Tablets, 200 mg, oral use Novartis Standard PR TEGRETOL ® CR carbamazepine controlled-release tablets Controlled-Release Tablets, 200 mg and 400 mg, oral use Novartis Standard PR TEGRETOL ® SUSPENSION carbamazepine suspension Suspension, 100 mg/5 mL, oral use Novartis Standard Anticonvulsant For Symptomatic Relief of Trigeminal Neuralgia Antimanic ATC code: N03AF01 Novartis Pharmaceuticals Canada Inc. 700 Saint-Hubert St., Suite 100 Montreal, Quebec H2Y 0C1 www.novartis.ca Date of Initial Authorization : Dec 31, 1969 Date of Revision: Feb 26, 2024 Submission Control Number: 273178 TEGRETOL is a registered trademark. _PR_ _TEGRETOL_ _®_ _ carbamazepine tablets, _ _PR_ _TEGRETOL_ _®_ _ CR carbamazepine controlled-release tablets, _ _PR_ _TEGRETOL_ _®_ _ SUSPENSION carbamazepine suspension _ _Page 2 of 49 _ _ _ RECENT MAJOR LABEL CHANGES None at the time of authorization TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 5 2 CONTRAINDICATIONS ................................................................................................... 5 Pročitajte cijeli dokument